Palisade Bio Appoints New CEO
Ticker: PALI · Form: 8-K · Filed: Sep 27, 2024 · CIK: 1357459
| Field | Detail |
|---|---|
| Company | Palisade Bio, Inc. (PALI) |
| Form Type | 8-K |
| Filed Date | Sep 27, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.01, $542,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-appointment
TL;DR
Palisade Bio just named Dr. Frampton as CEO, effective Sept 25th.
AI Summary
Palisade Bio, Inc. announced on September 27, 2024, that its Board of Directors appointed Dr. Jonathan M. Frampton as Chief Executive Officer, effective September 25, 2024. Dr. Frampton will also serve as a member of the Board. He previously held the position of Chief Medical Officer at the company.
Why It Matters
The appointment of a new CEO can signal a strategic shift or a renewed focus for the company, potentially impacting its future development and market performance.
Risk Assessment
Risk Level: medium — Leadership changes can introduce uncertainty regarding strategic direction and operational execution.
Key Players & Entities
- Palisade Bio, Inc. (company) — Registrant
- Dr. Jonathan M. Frampton (person) — Appointed CEO and Board Member
- September 27, 2024 (date) — Date of Report
- September 25, 2024 (date) — Effective Date of CEO Appointment
FAQ
Who has been appointed as the new Chief Executive Officer of Palisade Bio, Inc.?
Dr. Jonathan M. Frampton has been appointed as the new Chief Executive Officer of Palisade Bio, Inc.
When did the appointment of the new CEO become effective?
The appointment of Dr. Jonathan M. Frampton as CEO became effective on September 25, 2024.
What other role will Dr. Jonathan M. Frampton hold at Palisade Bio, Inc.?
In addition to CEO, Dr. Jonathan M. Frampton will also serve as a member of the Board of Directors.
What was Dr. Frampton's previous role at Palisade Bio, Inc.?
Dr. Frampton previously served as the Chief Medical Officer at Palisade Bio, Inc.
What is the filing date of this Form 8-K?
This Form 8-K was filed on September 27, 2024.
Filing Stats: 936 words · 4 min read · ~3 pages · Grade level 11.2 · Accepted 2024-09-27 16:31:12
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share PALI Nasdaq Capital Mark
- $542,000 — r. Finley (i) receives a base salary of $542,000 per year, (ii) is eligible to receive a
Filing Documents
- form8-k.htm (8-K) — 47KB
- ex10-01.htm (EX-10.01) — 74KB
- 0001493152-24-038547.txt ( ) — 312KB
- pali-20240927.xsd (EX-101.SCH) — 3KB
- pali-20240927_lab.xml (EX-101.LAB) — 33KB
- pali-20240927_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 27, 2024 Palisade Bio, Inc. By: /s/ J.D. Finley J.D. Finley Chief Executive Officer